(Q35041315)

6 August 2017

0 references

1 reference

title

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors (English)

1 reference

6 August 2017

Leanne M Kmet

1

1 reference

6 August 2017

Linda S Cook

series ordinal

2

1 reference

6 August 2017

Anthony M Magliocco

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

6 August 2017

16

1 reference

inferred from page(s)

published in

Cancer

1 reference

6 August 2017

97

1 reference

6 August 2017

2

1 reference

6 August 2017

389-404

1 reference

bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

Ovarian cancer: epidemiology, biology, and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Regulation of p53 function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Regulation and function of the p53 tumor suppressor protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53, the cellular gatekeeper for growth and division

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

The p53 tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 and HER-2/neu overexpression in ovarian borderline tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 Protein Expression and DNA Ploidy in Common Epithelial Tumors of the Ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Numerical chromosomal aberrations in borderline, benign, and malignant epithelial tumors of the ovary: correlation with p53 protein overexpression and Ki-67

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

An immunohistochemical study of p53 protein in ovarian mucinous neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Expression of cell regulatory proteins in ovarian borderline tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Immunohistochemical analysis of p53 in gynecologic tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 expression in ovarian borderline tumors and stage I carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Borderline tumors of the ovary: a clinico-pathologic and immunohistochemical study of 54 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Immunohistochemical analyses of sporadic and familial (185delAG carriers) ovarian cancer in Israel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Genetic alterations in ovarian borderline tumours and ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Biological malignancy grading in early-stage ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 accumulation in ovarian carcinomas and its prognostic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Prognostic significance of p53 immunostaining in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Increased frequency ofTP53 mutations inBRCA1 andBRCA2 ovarian tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Biomarker conservation in primary and metastatic epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

The combined evaluation ofp53 accumulation and of Ki-67 (MIBI) labelling index provides independent information on overall survival of ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 mutations and expression in ovarian cancers: correlation with overall survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Correlation of TP53 mutations and p53 expression in ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 gene analysis of ovarian borderline tumors and stage I carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

High incidence of mutations of the p53 gene detected in ovarian tumours by the use of chemical mismatch cleavage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 gene mutation in human borderline epithelial ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

p53 in tumour pathology: can we trust immunohistochemistry?--Revisited!

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Developments in the pathology of ovarian tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11064

7 January 2021

Identifiers

DOI

10.1002/CNCR.11064

1 reference

6 August 2017

1 reference